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Tour Inserm-CERVI, Lyon, FranceBackground & Aims: Hepatitis C virus (HCV) nonstructural pro-
tein 5A (NS5A) is a multifunctional protein playing a crucial role
in diverse steps of the viral replication cycle and perturbing mul-
tiple host cell pathways. We showed previously that removal of a
region in domain 2 (D2) of NS5A (mutant NS5AD2D) is dispens-
able for viral replication in hepatoma cell lines. By using a mouse
model and immune-competent cell systems, we studied the role
of D2 in controlling the innate immune response.
Methods: In vivo replication competence of NS5AD2Dwas studied
in transgenic mice with human liver xenografts. Results were val-
idated using primary human hepatocytes (PHHs) and mechanis-
tic analyses were conducted in engineered Huh7 hepatoma
cells with reconstituted innate signaling pathways.
Results: Although the deletion in NS5A removed most of the
interferon (IFN) sensitivity determining-region, mutant
NS5AD2D was as sensitive as the wild type to IFN-a and IFN-kJournal of Hepatology 20
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antivirals; Mengo Zn, Mengovirus Zn mutant.in vitro, but severely attenuated in vivo. This attenuation could
be recapitulated in PHHs and was linked to higher activation of
the IFN response, concomitant with reduced viral replication
and virus production. Importantly, immune-reconstituted
Huh7-derived cell lines revealed a sequential activation of the
IFN-response via RIG-I (retinoic acid-inducible gene I) and
MDA5 (Myeloma differentiation associated factor 5), respectively,
that was signiﬁcantly higher in the case of the mutant lacking
most of NS5A D2.
Conclusions: Our study reveals an important role of NS5A D2 for
suppression of the IFN response that is activated by HCV via RIG-I
and MDA5 in a sequential manner.
 2015 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
HCV is a positive strand RNA virus affecting 3% of the world
population. HCV is a major causative agent of liver diseases
including hepatosteatosis, ﬁbrosis, liver cirrhosis and hepatocel-
lular carcinoma. Chronicity of infection predominates as only
20% of infected individuals clear the virus spontaneously. This
low number illustrates efﬁcient virus escape from the immune
response, but the underlying molecular mechanisms are only
partially understood.
Innate immunity is the ﬁrst line of host defense against patho-
gen infection. Viral RNA can be recognized by pathogen recogni-
tion receptors such as Toll-like receptor 3 (TLR3) and RIG-I
(retinoic acid-inducible gene I)-like receptors (RLRs), such as
RIG-I or MDA5 (Myeloma differentiation associated factor 5).
These RLRs induce the activation of the interferon (IFN) regula-
tory factor-3 (IRF-3) resulting in transcription of type I and type
III IFN as well as a subset of IFN-stimulated genes (ISGs) such
as ISG56 [1,2]. Both RIG-I and MDA5 have different, but redun-
dant roles in pathogen recognition [3]. Upon RNA binding, they
recruit the adaptor protein MAVS (mitochondrial antiviral signal-
ing protein) [4], inducing phosphorylation and nuclear15 vol. 63 j 829–837
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translocation of IRF-3. This activation is disrupted by the viral
protease activity in nonstructural protein 3 (NS3) cleaving
MAVS and abrogating IRF3-dependent induction of the IFN
response [5].
In addition to NS3, NS5A has been implicated in counteracting
antiviral immune responses [6]. NS5A is composed of an
amino-terminal amphipathic a-helix responsible for membrane
association and three domains that are separated by
low-complexity sequences (LCSs). Domain 1 (D1) is highly struc-
tured and responsible for dimerization of NS5A. D3 is essential
for assembly of infectious HCV particles [7]. However, the role
of NS5A D2 for the viral life cycle is less well understood.
We reported earlier that removing most of NS5A D2 has no
effect on RNA replication or virus production in Huh7-derived
cells, which are most permissive for HCV [8]. By using a
mouse-based in vivo model, primary human hepatocytes
(PHHs) and engineered cell lines, we show here that NS5A D2
attenuates activation of type I and type III IFN response that is
induced by HCV via RIG-I and MDA5 in a sequential manner.Ti
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Fig. 1. Replication ﬁtness and IFN sensitivity of NS5A mutant. (A) HCV
genomes used in this study (numbers refer to aa positions of JFH-1). (B)
Replication of JcR2a or the JcR2a-5AD2D deletion mutant; means of triplicate
experiments ± SD. Western blot analysis of NS5A phospho-variants expressed inMaterial and methods
Plasmids and cells
The following plasmids have been described elsewhere: pFK Jc1-5AD2D (earlier
named pFK Jc1D2222-2280 [8]); pFK-J6/C3 (Jc1) [9]; pFK JcR2a [10]. Huh7.5 cells
were a kind gift of Dr. C.M. Rice, Rockefeller University, New York.
Primary human hepatocytes
PHHs were purchased from Biopredic (Rennes, France). Infection was performed
as described elsewhere [11].
Humanized mice
Livers of two- to four-weeks old male and female PXB-mice (uPA+/+/SCID) were
engrafted by injection of PHHs into the spleen. Mice with a blood concentration
of human albumin (h-alb) >6.0 mg/ml were selected for HCV infection. Each
mouse was inoculated with 106 TCID50 of Jc1 or Jc1-5AD2D (108 HCV RNA
copies per mouse). At different time points, blood was collected to quantify
h-alb and HCV RNA.
For further details related to Material and methods see Supplementary
materials.infected cells see left panel. (C, D) Virus titers in cells and culture supernatants
(means of triplicate experiments ± SD); n.s., no statistical signiﬁcance. (E, F) No
effect of D2 deletion on IFN sensitivity. Huh7.5 cells were infected and treated
with IFN-a (E) or IFN-k (F). Shown are means of triplicate measurements ± SD of a
representative experiment (n = 2).Results
Removal of most of NS5A D2 does not affect HCV replication and IFN
sensitivity in Huh7 cells
Although NS5A, most notably D2 containing the IFN-sensitivity
determining region (ISDR), has been implicated in resistance to
the antiviral activity of IFN, the underlying mechanism is poorly
deﬁned [12]. While complete removal of D2 abrogates HCV repli-
cation [13], consistent with an earlier report [8] we found that a
deletion spanning amino acid (aa) residues 2222 to 2280 of the
genotype 2a HCV isolate JFH1 does not affect RNA replication
as determined with an intragenotypic chimeric Renilla luciferase
reporter virus [10] (Fig. 1A and B). Moreover, this mutant (here
designated 5AD2D) produced amounts of infectious intra- and
extracellular virus particles comparable to wild type
(Fig. 1C and D). Although at early time points virus titers were
slightly higher in case of the mutant, the difference to wild type830 Journal of Hepatology 201was not statistically signiﬁcant. Importantly, this lack of phenotype
was not due to the use of the highly permissive cell clone Huh7.5,
because the same results were obtained with high-passage Huh7
cells (Supplementary Fig. 1). These results corroborated our
previous observations [8] and suggested that most of NS5A D2 is
dispensable for the HCV life cycle in hepatoma cell lines.
Since the deletion that we had introduced removed 75% of
the ISDR (reported for genotype 2a to reside between aa 2213–
2248 [12]), we wondered whether the mutant is more sensitive
to IFN. To this end, Huh7.5 cells were infected with JcR2a or
JcR2a-5AD2D and 24 h later treated for a period of 48 h with
increasing concentrations of IFN-a and IFN-k1 (Fig. 1E and F,
respectively). Both wild type and 5AD2D were equally sensitive
to these cytokines.5 vol. 63 j 829–837
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A deletion in NS5A D2 causes strong attenuation of HCV in vivo
Assuming that NS5A D2 might play a role in virus-host interac-
tion, not properly recapitulated in human hepatoma cells, we
determined replication ﬁtness of the 5AD2D mutant in vivo by
using the Alb-uPA+/+ xenograft mouse model. These animals suf-
fer from transgene-induced liver damage allowing xenografting
with primary human hepatocytes (PHHs) a few weeks after birth.
The mouse liver is progressively repopulated by human cells and
maintains normal metabolic functions [14]. Puriﬁed Jc1 and
Jc1-5AD2D virus particles of comparable quality were used for
injection of the animals (Fig. 2A). Seven transgenic mice with a
replacement index (RI) of PHHs in the mouse liver of >70%, as
deduced from serum concentration of human albumin (h-alb)
(Fig. 2B) and immunohistological analysis (Fig. 2C), were each
injected with 106 TCID50 of infectious HCV (corresponding to
108 RNA copies). Three animals were inoculated with Jc1
(mouse # 101, 102, 103) and 4 with Jc1-5AD2D (mouse # 201,
202, 203, and 204). Blood samples were collected periodically
to monitor h-alb levels and HCV RNA copy number (Fig. 3A) to
correlate viral replication with the RI by normalization to h-alb
levels. Already seven days after injection, high viral load was
detected in all three mice inoculated with Jc1 (Fig. 3B). On aver-
age, RNA load in these animals ﬂuctuated around 5  105 to 106
HCV RNA copies per mg h-alb (Fig. 3B; Supplementary Fig. 2). In
the case of animals injected with Jc1-5AD2D, two major differ-
ences were noticed. First, replication kinetic was profoundly
delayed in three of the four animals and only in one animal
HCV RNA could be detected in serum at day seven post inocula-
tion. Importantly, only at day 28 post inoculation, viremia was
detectable in all four animals. Second, on average, viremia in
these animals was ﬁvefold lower than in wild typeTC
ID 50
/m
l
pg
Co
re/
ml
RN
A
mo
lec
ule
s/m
l
Sp
ec
ific
inf
ec
tiv
ity
TC
ID 50
/m
l/p
g C
ore
Jc1
Jc1-5AD2Δ
A
C
B
101 102 103 201 202 203 204
0
5
10
15
Mouse #
Se
ru
m
h-
Al
b
(m
g/
m
l)
Mice Jc1 
Mice Jc1-5AD2Δ
100
102
106
104
108
1010
Jc1 (mouse #102)
Eosin stain Human cytokeratin 18
Jc1-5AD2Δ (mouse #203)
Human cytokeratin 18Eosin stain
Fig. 2. Characterization of virus inoculum and xenografted mice used for
in vivo test. (A) Quantiﬁcation of virus stocks used for inoculation of mice.
Amounts of infectious virus particles (TCID50/ml), Core protein and viral RNA
were determined. Speciﬁc infectivity corresponds to the ratio of virus titer and
amount of Core protein (TCID50/pg Core). (B) Quantiﬁcation of average human
serum human albumin (h-alb) amounts in each animal serum. (C) Repopulation
of mouse livers with PHHs. Shown are histological analyses of liver sections of
mouse #102 (Jc1) and #203 (Jc1-5AD2D). PHHs were visualized by Eosin staining
(dark red) or by immunohistology using an antibody recognizing human
cytokeratin 18 (blue stain).
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Fig. 3. Mutant Jc1-5AD2D is severely attenuated in vivo. (A) Schematic outline of
the experimental approach. (B) Scatter plot representing the time course of HCV
viremia in serum of mice injected with Jc1 (black squares) or Jc1-5AD2D (red
triangles). HCV RNA amounts were normalized to h-alb levels of the respective
mouse. The dotted line (103 RNA copies per mg h-alb) indicates our limit of
detection. (C) Summary of the conserved nucleotide substitutions detected in
mice at day 74.
Journal of Hepatology 201virus-inoculated mice (2  105 HCV RNA copies per mg h-alb;
Fig. 3B and Supplementary Fig. 2). While in Jc1-infected mice, vir-
emia was rather stable throughout the experiment, in all
Jc1-5AD2D virus-inoculated animals viremia steadily increased
up to day 42–49 (Fig. 3B and Supplementary Fig. 2). This was
not due to higher cytopathogenicity of the mutant virus, because
immune histological analysis revealed comparable growth of
transplanted human hepatocytes (Fig. 2C), consistent with the
comparable RI in wild type and mutant virus-inoculated animals.
These results suggest that Jc1-5AD2D is strongly attenuated
in vivo, arguing that NS5A D2 is an important ﬁtness determinant.
This is not due to replication or virus production per se, as the
attenuation was not found in Huh7 cells.
Gain of ﬁtness of Jc1-5AD2D in vivo does not result from adaptive
mutations
Since RNA copy numbers detected in Jc1-5AD2D-inoculated mice
steadily increased during the observation period and reached5 vol. 63 j 829–837 831
BA
Jc1
Jc1-5AD2Δ
2ronoDsHHP1ronoDsHHP
0 1 2 3 4 5 6 7 8 9 10
101
102
103
104
105
106
107
Days post-infection
Days post-infection
Days post-infection
Days post-infection
Days post-infection Days post-infection
Days post-infection
Days post-infection
Days post-infection
Days post-infection
H
C
V 
ex
tra
ce
llu
la
r i
nf
ec
tiv
ity
(T
C
ID
50
/m
l)
0 1 2 3 4 5 6 7 8 9 10
101
102
103
104
105
**
*
*
*
aa
H
C
V 
ex
tra
ce
llu
la
r i
nf
ec
tiv
ity
(T
C
ID
50
/m
l)
0 1 2 3 4 5 6 7 8 9 10
0
2
4
6
8
10
12
14
16
HC
V
RN
A
(fo
ld
in
du
ct
io
n)
0 1 2 3 4 5 6 7 8 9 10
0
2
4
6
HC
V
RN
A
(fo
ld
in
du
ct
io
n)
***
***
*** *** ***
*
*
bb
0 1 2 3 4 5 6 7 8 9 10
0.1
1
10
100
1,000
IF
N
-β
 m
R
N
A 
le
ve
ls
(fo
ld
 in
du
ct
io
n)
0 1 2 3 4 5 6 7 8 9 10
0.1
1
10
100
1,000
***
*
***
***
**
***
*
cc
0 1 2 3 4 5 6 7 8 9 10
0.1
1
10
100
1,000
IF
N
-λ
 m
R
N
A 
le
ve
ls
(fo
ld
 in
du
ct
io
n)
0 1 2 3 4 5 6 7 8 9 10
0.1
1
10
100 ***
***
****
***
**
**
***
dd
0 1 2 3 4 5 6 7 8 9 10
0.1
1
10
100
1,000
10,000
100,000
IS
G
56
m
RN
A
l e
ve
ls
(fo
ld
 in
du
ct
io
n)
0 1 2 3 4 5 6 7 8 9 10
0.01
0.1
1
10
100
1,000
10,000
*
* *
*
**
ee
IS
G
56
m
RN
A
le
v e
ls
(fo
ld
 in
du
ct
io
n)
IF
N
-λ
 m
R
N
A 
le
ve
ls
(fo
ld
 in
du
ct
io
n)
IF
N
-β
 m
R
N
A 
le
ve
ls
(fo
ld
 in
du
ct
io
n) ***
Research Article
832 Journal of Hepatology 2015 vol. 63 j 829–837
JOURNAL OF HEPATOLOGY
wild type levels at later time points, we reasoned that adaptive
mutations restoring ﬁtness might have emerged. Therefore, total
RNA was isolated from the serum of the animals, HCV cDNAs
were ampliﬁed in two overlapping fragments and cloned as
described previously (note that no amplicon was obtained for
mouse #103) [15]. The ﬁrst fragment spanned the coding region
of Core to the end of NS3; the second fragment the region encod-
ing most of NS3 to the end of NS5B. For each amplicon derived
from a given animal, at least three cDNA clones were analyzed
(Supplementary Fig. 3). Only nucleotide substitutions conserved
in all three cDNA clones were considered. Substitutions present
in both Jc1 and Jc1-5AD2D genomes were disregarded, because
they reﬂected genetic variability independent from speciﬁc adap-
tation of the mutant. As summarized in Fig. 3C, three of the four
mutant virus-inoculated animals (# 201, 202, and 204) contained
HCV variants with aa substitutions in both structural and non-
structural protein coding regions. Importantly, no substitution
was found in HCV genomes extracted from mouse #203.
Although we cannot exclude that minor HCV variants or muta-
tions conserved in less than three of the analyzed cDNA clones
conferred growth advantage in the animals, these results sug-
gested that the increase of Jc1-5AD2D replication over time might
be independent from speciﬁc adaptive mutations in the HCV cod-
ing regions. The data therefore argued for a complex virus – host
cell co-adaptation.
NS5A D2 is important to suppress the interferon response in primary
human hepatocytes
Since an adaptive immune response is lacking in the
Alb-uPA+/+SCID mouse model, we reasoned that differences in
the cytokine response, most notably the IFN system, might have
been the cause for the attenuation of mutant Jc1-5AD2D. Since
this difference was not observed in Huh7 cells, we tested our
assumption by using PHHs that are IFN-competent. Cells derived
from two donors were infected with Jc1 or Jc1-5AD2D at a MOI of
1 TCID50 per cell (Fig. 4; for details of donors see Supplementary
Fig. 4). Supernatants and cells were harvested at regular intervals
and amounts of infectious extracellular virus particles were
determined by limiting dilution assay (Fig. 4Aa and Ba).
Intracellular HCV RNA levels (Fig. 4Ab and Bb) and mRNA levels
of three ISGs, ISG56, IFN-b, and IFN-k, were quantiﬁed by
qRT-PCR (Fig. 4Ac-e and Bc-e). In spite of profound
donor-to-donor variation, ISG56 and IFN mRNA levels were
strongly induced by Jc1 infection reaching maximal levels at
day two or three post-infection (p.i.). This induction correlated
with ampliﬁcation kinetic of HCV RNA and virus production,
reaching peak levels already at day two p.i., and was followed
by a sharp decline of viral RNA and virus amounts, arguing for
potent suppression of HCV replication by the induced antiviral
response. Importantly, Jc1-5AD2D infection induced a signiﬁ-
cantly stronger IFN response in both donors, correlating well with
rapid suppression of viral RNA replication and virus production.
Variability in the magnitude of ISG and IFN induction observedFig. 4. Attenuation of Jc1-5AD2D replication in PHHs correlates with enhanced acti
infected with Jc1 (black lines) or the Jc1-5AD2D mutant virus (grey lines). At given time
were determined. HCV RNA as well as IFN-b, IFN-k1, and ISG56 mRNA levels were det
samples. Shown are fold induction of gene expression relative to non-infected cells. Sta
Journal of Hepatology 201with PHHs from donor 1 and 2 correlated with HCV replication
level (Fig. 4A and B). Thus, NS5A D2 plays an important role in
controlling kinetics and magnitude of the IFN response against
HCV infection, thus providing an explanation for the attenuation
of the NS5A deletion mutant in vivo.
Taking advantage of this system, we tested the possible
impact of some of the mutations detected in HCV genomes repli-
cating in the infected mice on replication ﬁtness. Although the
absence of mutations in animal #203 argued against adaptation
of the virus (Fig. 3C), we generated a Jc1-5AD2D variant contain-
ing all four mutations present in HCV of animal #202 (Fig. 3C).
These mutations resided in E2 (K410E, N534D), NS2 (A944T),
and NS5A (T2220A). This variant, designated Jc1-5AD2Dmut202,
was used to inoculate PHHs from a third donor, in parallel to
Jc1 and the parental Jc1-5AD2D mutant. As shown in
Supplementary Fig. 5, highest replication was again found with
the wild type. Although IFN response obtained with PHHs of this
donor were rather low, both the parental NS5A deletion mutant
and the variant Jc1-5AD2Dmut202 induced a higher IFN-b and
ISG56 response than wild type. Importantly, replication and virus
production of these variants were comparable, but signiﬁcantly
lower than wild type. These results corroborate the important
role of NS5A D2 in attenuating the IFN response and support fur-
ther the absence of adaptive mutations in Jc1-5AD2D genomes
replicating in infected mice.
Activation of the interferon response by HCV via MDA5
Although results obtained with PHHs provided ﬁrst insights into
the mechanism of attenuation, this cell system is limited by poor
availability, high donor-to-donor variation and technical difﬁcul-
ties to manipulate the cells. Therefore, we attempted to establish
Huh7-based cell systems allowing the recapitulation of pheno-
types observed in PHHs. However, Huh7 cells induce poor ISG
expression upon virus infection and have a very low IFN produc-
tion [16]. Moreover, Huh7.5 cells that are most permissive to HCV
infection, express very low amounts of MDA5 and have a defec-
tive RIG-I gene [5]. To overcome these impairments, we used pre-
viously described Huh7.5 cells stably expressing functional RIG-I
[17] and generated in addition analogous cell lines expressing
ectopically MDA5 (Huh7.5 MDA5 cells) or the empty expression
vector (Huh7.5 Ctrl cells) (Fig. 5A).
To determine restoration of RNA sensing and activation of the
IFN response, cells were co-transfected with a reporter plasmid
containing the ISG56 promoter sequence upstream of the Fireﬂy
luciferase gene and a control plasmid encoding Renilla luciferase
to normalize for transfection efﬁciency. Six hours post transfec-
tion, cells were stimulated with the synthetic double-stranded
RNA (dsRNA) analogue poly(I:C) for 16 h. ISG56 promoter activity
was induced 15-fold in both RIG-I and MDA5 overexpressing
cell lines relative to non-stimulated cells (Fig. 5B). As alternative
stimulus, we chose Sendai virus (SeV) infection that was shown
to be sensed exclusively by RIG-I [3]. Indeed, SeV infection stim-
ulated exclusively ISG56 promoter activity in Huh7.5 RIG-I cells,vation of the IFN response. PHHs of two donors (A, Donor 1; B, Donor 2) were
points after infection, supernatants were harvested and extracellular virus titers
ermined by qRT-PCR. Results were normalized to values obtained with day one
tistical signiﬁcance is shown in the top.
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Research Articlebut not in Huh7.5 MDA5 cells (Fig. 5B). These results show that
RNA sensing and activation of IRF-3 dependent signaling are
effective in Huh7.5 RIG-I and MDA5 cells.
We next determined whether also HCV infection is recognized
by either RLR. Cells were infected with Jc1 and 48 h later, ISG56
promoter activation was determined. Consistent with our earlier
report, HCV infection did not activate the ISG56 reporter in
Huh7.5 RIG-I cells [17]. Surprisingly, however, a
MOI-dependent activation of ISG56 promoter was observed in
Huh7.5 MDA5 cells (Fig. 5C). This activation was speciﬁc and
dependent on viral replication, because infection of these cells
with UV-inactivated Jc1 did not induce an IFN response
(Fig. 5D). Moreover, suppression of HCV replication by the NS3
protease inhibitor telaprevir or the nucleoside analogue
20-C-methylcytidine (20-CMC) potently suppressed activation of
the IFN response (Fig. 5E). Finally, we found that transient
expression of the V protein from parainﬂuenza virus 5 (PIV5), a
well-described inhibitor of MDA5 [18], in Huh7.5 MDA5 cells
impaired HCV-induced ISG56 promoter activation (Fig. 5F).
Altogether these results demonstrate that HCV is sensed by
MDA5 which required viral replication.
HCV activates the interferon response via RIG-I and MDA5 in a
sequential manner
Taking advantage of the Huh7.5 cell lines with restored HCV
sensing, we compared activation of the RIG-I and MDA5 pathway
between Jc1 and the Jc1-5AD2D mutant. To include possible dif-
ferences in activation kinetics, we conducted a time course834 Journal of Hepatology 201experiment. In addition to Huh7.5 control (Ctrl) cells, we
included a Huh7.5-derived cell line stably expressing a MDA5
mutant lacking the caspase activation and recruitment domain
(CARD; Huh7.5 MDA5DCARD cells). Cells were infected at a
MOI of 10 TCID50 per cell and ISG56 promoter activity was deter-
mined. We observed a temporal activation of the RIG-I mediated
IFN response that was detectable 10 h p.i., lasted until 24 h p.i.
and was no longer measurable 40 h p.i. (Fig. 6A). This result
was consistent with our earlier report and indicated rapid and
efﬁcient control of RIG-I signaling by HCV [17]. Interestingly,
the decrease in activation of RIG-I was concomitant with an acti-
vation of the MDA5 signaling pathway that was strongly detect-
able 40 h p.i. (Fig. 6A). This activation was speciﬁc and not found
with Huh7.5 MDA5DCARD cells. Moreover, this sequential activa-
tion of RIG-I and MDA5 was also obtained with poly(I:C) arguing
that this kinetic is intrinsic to these RLRs (Supplementary Fig. 6).
Most strikingly, although Jc1-5AD2D infection led to a similar
sequential activation of RLRs, the kinetic was faster leading to
higher levels of ISG56 promoter activation 10 h and 40 h p.i. in
case of RIG-I and MDA5, respectively (Fig. 6A). Jc1 and
Jc1-5AD2D infectivity titers of supernatants collected from the
infected cell lines were comparable, thus excluding the possibil-
ity that the observed differences were caused by different
amounts of viral RNA inducer (Fig. 6B).
Although Huh7.5 RIG-I cells have an impaired type I IFN pro-
duction, they can release type III IFN by using a strong stimulus
such as SeV infection (data not shown). Thus, it was possible that
the observed ISG56 activation was caused by IFN released from
infected cells rather than by direct HCV-mediated IRF3 activation.5 vol. 63 j 829–837
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To differentiate between these possibilities, we characterized the
supernatants collected from HCV infected cell lines for the pres-
ence of IFN by using a highly sensitive HCV-based bioassay [19].
However, in spite of high sensitivity of this assay, no antivirally
active IFN could be detected (Supplementary Fig. 7) arguing
against IFN-mediated ampliﬁcation of the ISG56-based read-out.
The sequential activation of RIG-I and MDA5 that both signal
via MAVS was perplexing. On one hand, both Jc1 and Jc1-5AD2D
efﬁciently control RIG-I signaling by NS3-mediated MAVS cleav-
age; on the other hand, we observed robust activation of MDA5
at late time points after infection when the amounts of NS3 are
clearly higher than at early time points (Supplementary Fig. 8).
This raised the question whether MDA5 activation was indeed
mediated by MAVS or some other, undeﬁned pathway. To address
this possibility, we generated Huh7.5 MDA5 cell lines stably
expressing the NS3/4A protease efﬁciently cleaving and inactivat-
ing MAVS. Huh7.5 MDA5 cells expressing a Ctrl plasmid and
MDA5DCARD cells were used as control. Upon infection of these
cells with Jc1 or Jc1-5AD2D, MDA5-mediated signaling was
severely impaired by the protease showing that HCV-induced
activation of the IFN system by MDA5 was also mediated by
MAVS (Fig. 6C).
In an attempt to determine the impact of NS5A on IFN signal-
ing more directly, we generated Huh7.5 RIG-I and Huh7.5 MDA5
cells stably overexpressing NS5A or 5AD2D. To this end the NS5A
proteins were expressed out of the polyprotein context toA
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Journal of Hepatology 201exclude confounding effects that might be exerted by other
HCV proteins such as the NS3 protease (Fig. 7A). Induction of
ISG56 and IFN-k1 mRNAs was measured upon infection with
SeV or a mengovirus Zn mutant (Mengo Zn) [20] triggering
RIG-I or MDA5, respectively (Fig. 7B and C). Interestingly, wild
type NS5A repressed ISG induction by either RLR, but this repres-
sion was reduced in the case of NS5AD2D. Importantly, the degree
of reduction was in the range of the difference observed between
NS5A and NS5AD2D in the ISG56 promoter assay.
In conclusion, our results show that HCV activates RIG-I and
MDA5 signaling pathways in a sequential and MAVS-dependent
manner. Importantly, this activation is suppressed by D2 of
NS5A, thus providing an explanation for the attenuation of the
mutant lacking part of D2 both in PHHs and in vivo.Discussion
We report that HCV activates RIG-I- and MDA5-mediated signal-
ing in a sequential manner. The observation that poly(I:C) acti-
vates both RLRs with similar kinetics argues for an intrinsic
property of these sensors and the corresponding signaling path-
way. Nevertheless, in HCV-infected cells strand-speciﬁcity of
RLRs might be of relevance with RIG-I detecting preferentially
incoming (single-strand) RNA whereas MDA5 likely recognizes
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Research Articlereplication cycle. We note that such a complementary role of
RIG-I and MDA5 and the temporal detection of PAMPs was previ-
ously reported for West Nile Virus [21,22].
Our results are in perfect agreement with a very recent study
by Cao and colleagues also showing that MDA5 senses HCV RNA
[23]. Moreover, these authors found that MDA5 is more relevant
than RIG-I with respect to activation of the IFN response by HCV.
Thus far it is unclear what is recognized by MDA5 and how
MDA5-mediated signaling is achieved at such late time points
after infection when most of MAVS is cleaved by the viral NS3
protease. At least two possibilities can be envisaged: ﬁrst,
MDA5 is activated by a subpopulation of MAVS poorly accessible
to the protease such as peroxisomal MAVS [24]; second, MAVS
cleavage is not complete and a small fraction, not detectable by
our assays, might sufﬁce to activate the IFN response, particularly
via MDA5.
In agreement with previous reports [25,26], we observed an
activation of the IFN response by HCV via TLR3 (Supplementary
Fig. 9). Importantly the peak of activation occurred only at 72 h
p.i. and no difference in the level of ISG56 promoter activation
could be observed between Jc1 and Jc1-5AD2D arguing that NS5A
D2 preferentially affects cytosolic and not endosomal RNA sensors.836 Journal of Hepatology 201NS5A was proposed to perturb IFN and NF-jB signaling path-
ways through interaction with several factors, most notably PKR
and TRAF2 [6]. However, no evidence for such interactions or dif-
ferential activation of PKR by wild type and 5AD2D was found
(Supplementary Fig. 10A–C). Apart from a possible modulation
of PKR- and NF-jB-dependent pathways, the NS5A deletion
mutation might have lower control of IFN-activation because of
altered RNA secondary structure or shorter RNA length, rather
than exerting an effect at the protein level. However, when we
transfected our engineered Huh7.5 cells with Jc1 or Jc1-5AD2D
RNA, the IFN response was stimulated to the same extent
(Supplementary Fig. 10D). Thus, it is unlikely that the deletion
introduced into NS5A altered RNA structure in a way to make it
a better ligand for RIG-I and MDA5. Alternatively, NS5A is a
RNA binding protein with all three domains contributing to
nucleic acid binding, albeit to different extents [27]. Thus,
removal of D2 might affect NS5A binding afﬁnity to viral RNA,
resulting in inefﬁcient shielding of the genome, and thereby bet-
ter detection by RIG-I and MDA5, leading to higher activation of
the IFN system.
Although 5AD2D lacks two-thirds of the C-terminal of ISDR, a
region suggested to be involved in the outcome of IFN treatment
[28], we found that this deletion did not affect HCV sensitivity to
IFN-a and IFN-k1. Moreover, neither NS5A nor NS5AD2D stably
expressed in the context of the polyprotein NS3-5A affected
JAK-STAT signaling pathway as determined by the degree of
STAT1 phosphorylation and ISG induction upon IFN treatment
(Supplementary Fig. 11). These results corroborate previous ﬁnd-
ings showing that ISDR mutations found in HCV-infected individ-
uals and associated with IFN sensitivity do not inﬂuence HCV IFN
response [29]. Importantly, this was found both with the JFH-1
isolate that we also used in our study, and with chimeric
genomes containing NS5A sequences of other genotypes [30],
arguing that IFN sensitivity per se is not directly linked to the
ISDR.
It has been shown that HCV induces ISGs in the liver of
infected patients [31]. Paradoxically, the level of induction corre-
lates inversely with response to IFN-based therapy [31]. Although
no experimental data are available, based on the results reported
here it is tempting to speculate that higher ISG pre-activation
might be due to distinct mutations in NS5A D2, thus providing
a possible explanation for the correlation of ISDR signatures with
outcome of IFN therapy [12,32].
In conclusion, we report a sequential activation of the IFN
response upon HCV infection via RIG-I and MDA5 and a suppres-
sion of this response in a NS5A D2-dependent manner. This inhi-
bition might contribute to the high rate of HCV persistence.Financial support
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